Literature DB >> 577336

Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism.

L Mosekilde, F Melsen, J P Bagger, O Myhre-Jensen, N Schwartz Sorensen.   

Abstract

Iliac-crest biopsies were obtained from 40 untreated hyperthyroid patients after double-labelling with tetracycline. Histomorphometric analyses were performed on undecalcified and decalcified bone sections. The morphometric and chemical data were compared with those in normal control groups and the results of the morphometric analyses were related to thyroid function and to chemical quantities of calcium-phosphorus metabolism. The bone turn-over was increased in the hyperthyroid patients with an increase both in bone resorption and bone formation. Serum alkaline phosphphatase was increased and positively correlated to the amount of osteoid and to the extent of tetracycline-labelled surfaces. The osteoclastic resorption was positively and the bone formation inversely correlated to thyroid activity. This might explain the reduced amount of trabecular bone found in hyperthyroidism. The most striking feature was, however, a pronounced increase in osteoclastic activity in cortical bone followed by increased porosity. The osteoclastic resorption in cortical bone was positively correlated to serum concentrations and urinary excretions of calcium and phosphorus. This indicates that increased cortical osteoclastic resorption is mainly responsible for bone mineral mobilisation in hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 577336     DOI: 10.1530/acta.0.0850515

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  25 in total

Review 1.  The pathophysiology and clinical aspects of hypercalcemic disorders.

Authors:  D B Lee; E T Zawada; C R Kleeman
Journal:  West J Med       Date:  1978-10

Review 2.  Calcium metabolism in thyroid disease.

Authors:  G Benker; N Breuer; R Windeck; D Reinwein
Journal:  J Endocrinol Invest       Date:  1988-01       Impact factor: 4.256

3.  Bone mineralization and calciotropic hormones in children with hyperthyroidism. Effects of methimazole therapy.

Authors:  G Saggese; S Bertelloni; G I Baroncelli
Journal:  J Endocrinol Invest       Date:  1990 Jul-Aug       Impact factor: 4.256

4.  Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?

Authors:  Tina Z Belsing; Charlotte Tofteng; Bente L Langdahl; Peder Charles; Ulla Feldt-Rasmussen
Journal:  Nutr Metab (Lond)       Date:  2010-09-01       Impact factor: 4.169

5.  High-normal free thyroxine levels are associated with low trabecular bone scores in euthyroid postmenopausal women.

Authors:  Y Hwangbo; J H Kim; S W Kim; Y J Park; D J Park; S Y Kim; C S Shin; N H Cho
Journal:  Osteoporos Int       Date:  2015-08-08       Impact factor: 4.507

6.  Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSH.

Authors:  A N Gam; G F Jensen; K Hasselstrøm; M Olsen; K S Nielsen
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

Review 7.  Coexisting hyperparathyroidism with thyrotoxicosis.

Authors:  D M McGowan; A Vaswani; I Shperling
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

8.  Effects of thyroxine on cortical bone remodeling in adult dogs: a histomorphometric study.

Authors:  W B High; C C Capen; H E Black
Journal:  Am J Pathol       Date:  1981-03       Impact factor: 4.307

9.  Serum concentrations of osteocalcin in patients with hyperthyroidism, hypothyroidism and subacute thyroiditis.

Authors:  N Kojima; S Sakata; S Nakamura; K Nagai; H Takuno; T Ogawa; I Matsui; H Sarui; K Miura
Journal:  J Endocrinol Invest       Date:  1992 Jul-Aug       Impact factor: 4.256

10.  Effect of thyrotoxicosis and its treatment on mineral and bone metabolism.

Authors:  J D Lalau; J L Sebert; A Marie; A Fournier; J Quichaud
Journal:  J Endocrinol Invest       Date:  1986-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.